Search Medical Condition
Please enter condition
Please choose location

Sabadell(Barcelona), Spain Clinical Trials

A listing of Sabadell(Barcelona), Spain clinical trials actively recruiting patients volunteers.

RESULTS

Found (425) clinical trials

Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy

To evaluate whether albumin administration after an episode of hepatic encephalopathy ( grade II) improves survival at 30, 90 and 180 days. to evaluate the effects of albumin on hepatic encephalopathy recurrence during the study period. To analyze whether albumin administration reduces hospitalization requirement. To study the effects of albumin ...

Phase

0.0 miles

Learn More »

Abdominoperineal Extra-Elevators Rectal Resection for Cancer: Prone Position vs. Supine Position

Prospective multicenter randomized controlled trial comparing the prone vs. the supine position of the perineal time of the Miles operation in patients with advanced rectal cancer. Primary objective: Pathological circumferential resection margin Secondary objectives: 5 year oncological outcomes Morbimortality rates Surgical specimen quality Perineal hernia incidence

Phase N/A

0.0 miles

Learn More »

Observational Study to Evaluate the Use of Targeted Therapies in Metastatic Colorectal Cancer

The purpose of this study is to evaluate, in terms of overall survival, the benefit of monoclonal antibodies in the start time of the diagnosis of advanced disease or administer a deferred basis after progression to treatment with chemotherapy alone.

Phase N/A

0.0 miles

Learn More »

Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol

Study data Data will be collected on all eligible patients who undergo elective lower gastrointestinal surgery within any compliance of an ERAS protocol during the study months. Only routine clinical data will be included and where this is unavailable the domain will be left blank e.g. patients who do not ...

Phase N/A

0.0 miles

Learn More »

European Low and Intermediate Risk Neuroblastoma Protocol

LOW RISK STUDY The low risk group of patients includes NB patients without MYCN amplification with or without life threatening symptoms in the following clinical situations: Children aged 18 months with localised neuroblastoma associated with image defined risk factors precluding upfront surgery (stage INRG L2). Children aged 12 months with ...

Phase

0.0 miles

Learn More »

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

This is an event driven study to reach statistical power given all other assumptions. Subjects will visit the clinic 1 month after randomization and at regular intervals thereafter. Additionally, for any subject prematurely discontinuing study medication, assessments will be conducted every 6 months for the collection of study endpoints. Those ...

Phase

0.0 miles

Learn More »

Phase III Radium 223 mCRPC-PEACE III

The objective of this randomized phase III open label trial is to assess if upfront combination of enzalutamide and Ra223 improves radiological progression-free survival compared to enzalutamide single agent in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone.

Phase

0.0 miles

Learn More »

A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer

Subjects will be enrolled in a targeted 1:1 stratification ratio into 1 of 2 chemotherapy treatment arms at the investigator's discretion: carboplatin plus paclitaxel or carboplatin plus Pegylated Liposomal Doxorubicin (PLD), and then randomized in a 2:1 ratio to receive weekly farletuzumab 5 mg/kg or placebo (ie, Test Article). All ...

Phase

0.0 miles

Learn More »

Zimmer POLAR Persona - TKA (EMEA Study)

This is a prospective, multicenter, non-controlled study of the commercially available Persona knee implants. The study will require each site to obtain Ethics approval prior to study enrollment. All potential study subjects will be required to participate in the Informed Consent Process. Study subjects will undergo preoperative clinical evaluations prior ...

Phase N/A

0.0 miles

Learn More »

MLN0128 in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy

The drug being tested in this study is called MLN0128. MLN0128 is being tested to treat postmenopausal women with advanced or metastatic estrogen receptor (ER) positive, human epidermal growth factor receptor-2 (HER2) negative breast cancer that has progressed during or after aromatase inhibitor (AI) therapy. This study will evaluate the ...

Phase

0.0 miles

Learn More »